These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9855405)

  • 1. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized.
    Bronner U; Brun R; Doua F; Ericsson O; Burri C; Keiser J; Miézan TW; Boa YF; Rombo L; Gustafsson LL
    Trop Med Int Health; 1998 Nov; 3(11):913-7. PubMed ID: 9855405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigations of the metabolites of the trypanocidal drug melarsoprol.
    Keiser J; Ericsson O; Burri C
    Clin Pharmacol Ther; 2000 May; 67(5):478-88. PubMed ID: 10824626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phenomenon of treatment failures in Human African Trypanosomiasis.
    Brun R; Schumacher R; Schmid C; Kunz C; Burri C
    Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness.
    Na-Bangchang K; Doua F; Konsil J; Hanpitakpong W; Kamanikom B; Kuzoe F
    Eur J Clin Pharmacol; 2004 Jun; 60(4):269-78. PubMed ID: 15141331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
    Matovu E; Enyaru JC; Legros D; Schmid C; Seebeck T; Kaminsky R
    Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of melarsoprol in biological fluids by high-performance liquid chromatography and characterisation of two stereoisomers by nuclear magnetic resonance spectroscopy.
    Ericsson O; Schweda EK; Bronner U; Rombo L; Fridén M; Gustafsson LL
    J Chromatogr B Biomed Sci Appl; 1997 Mar; 690(1-2):243-51. PubMed ID: 9106049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the trypanocidal drug melarsoprol and its conversion products in biological fluids with HPLC-ICPMS/ESMS.
    Raber G; Raber T; Raml R; Murko M; Magnes C; Francesconi KA
    Talanta; 2013 Nov; 116():876-81. PubMed ID: 24148488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
    Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
    J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An automated biological assay to determine levels of the trypanocidal drug melarsoprol in biological fluids.
    Onyango JD; Burri C; Brun R
    Acta Trop; 2000 Jan; 74(1):95-100. PubMed ID: 10643913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of the trypanocidal drug melarsoprol.
    Burri C; Baltz T; Giroud C; Doua F; Welker HA; Brun R
    Chemotherapy; 1993; 39(4):225-34. PubMed ID: 8391966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
    Pyana Pati P; Van Reet N; Mumba Ngoyi D; Ngay Lukusa I; Karhemere Bin Shamamba S; Büscher P
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3212. PubMed ID: 25275572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
    Jansson-Löfmark R; Na-Bangchang K; Björkman S; Doua F; Ashton M
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1299-307. PubMed ID: 25512417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid.
    Burri C; Brun R
    Trop Med Parasitol; 1992 Dec; 43(4):223-5. PubMed ID: 1293724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness.
    Schmid C; Nkunku S; Merolle A; Vounatsou P; Burri C
    Lancet; 2004 Aug 28-Sep 3; 364(9436):789-90. PubMed ID: 15337407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.
    Burri C; Nkunku S; Merolle A; Smith T; Blum J; Brun R
    Lancet; 2000 Apr; 355(9213):1419-25. PubMed ID: 10791526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An alternative form of melarsoprol in sleeping sickness.
    Kennedy PG
    Trends Parasitol; 2012 Aug; 28(8):307-10. PubMed ID: 22704910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
    Maina N; Maina KJ; Mäser P; Brun R
    Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative application of melarsoprol for treatment of T. B. gambiense sleeping sickness. Preliminary results.
    Burri C; Blum J; Brun R
    Ann Soc Belg Med Trop; 1995 Mar; 75(1):65-71. PubMed ID: 7794064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment.
    Lejon V; Lardon J; Kenis G; Pinoges L; Legros D; Bisser S; N'Siesi X; Bosmans E; Büscher P
    Trans R Soc Trop Med Hyg; 2002; 96(3):329-33. PubMed ID: 12174791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
    Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F
    Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.